Two ASX Microcaps Quietly Building Long-Term Value

Bioxyne (ASX: BXN) and Marmota (ASX: MEU)

When it comes to investing in microcap stocks, the usual narrative is either explosive short-term runs or quiet obscurity. But every so often, a handful of companies take a different path—choosing to methodically lay down long-term foundations instead of chasing fleeting hype. Two such ASX microcaps are Bioxyne (BXN) and Marmota (MEU).

While they operate in very different industries—advanced health manufacturing and gold exploration—the common thread is their focus on de-risking, compounding, and growing steadily. Let’s take a closer look at how both are quietly carving out sustainable value for their investors.

Bioxyne (BXN): From Probiotic Brand to Profitable GMP Manufacturer

Bioxyne has undergone one of the more striking transformations among ASX microcaps. For years, it was primarily known as a small health and probiotics brand. But FY25 marked a major turning point: the company successfully pivoted into advanced manufacturing with a strong focus on medicinal cannabis and psychedelics.

This shift wasn’t just a story—it showed up in the numbers.

• FY25 revenue: $29.6 million, representing a massive 217% year-on-year increase. This surge was fueled by the commencement of in-house medicinal cannabis manufacturing in August 2024, alongside several large-scale supply contracts.
• FY25 net profit: $4.9 million, a stark turnaround from the $12.8 million loss in FY24. This equates to a healthy 16% profit margin.
• Strategic backdrop: Bioxyne’s expanded manufacturing licence now covers a wide scope—cannabis flower, oils, gummies, as well as MDMA and psilocybin. The company has evolved into a scaled contract manufacturer serving over 100 customers, generating around $30 million in annual revenues.

Why BXN is building value

The appeal of Bioxyne lies in its new operating model. Unlike retail-heavy health brands that burn cash on marketing, BXN now enjoys recurring B2B revenues, scalable margins, and a capital-light path to growth.

If its UK, EU, and Japanese operations regain momentum alongside the strong Australian base, investors could see significant operating leverage flow through into FY26. In short, BXN is no longer just a microcap health story—it’s a profitable manufacturing platform with global upside.

Marmota (MEU): Unlocking a New Gold District at Greenewood

On the other end of the spectrum, Marmota is slowly assembling what could be one of South Australia’s most promising emerging gold districts. Its flagship Gawler Gold Project has long revolved around the Aurora Tank discovery, but the narrative has shifted with its new Greenewood discovery.

Here’s what has been happening on the ground:

• Drilling program: Marmota recently completed a maiden drill campaign at Greenewood, consisting of 146 RC holes totaling 15,480 metres. Interestingly, the program was expanded twice mid-way, up from an initial 127 holes/10,000 metres—an encouraging sign of early promise. The average hole depth was around 106 metres.
• Ownership: The Greenewood target sits within the Golden Moon JV area, where Marmota holds a 90% stake via Half Moon. It is strategically located about 35 km northwest of Aurora Tank and 30 km northeast of the Challenger mine.
• District context: Historical exploration at Greenewood has been minimal, with only 8,245 metres drilled across 126 holes in the past. Against today’s robust $5,200/oz AUD gold price—more than three times 2018 levels—near-surface discoveries here could deliver meaningful economics.

Why MEU is building value

For years, Marmota was seen as a “single deposit explorer” at Aurora Tank. Greenewood changes that. It expands the story into a multi-target district play, offering multiple shots on goal in a rising gold market.

With assays from Greenewood expected soon, the potential for fast resource growth is real. Even moderate gold grades could translate into attractive economics, especially given the strong tailwinds in the Australian gold price environment.

What Investors Should Watch Next

Both companies are at inflection points. Here’s what could move the needle in the near future:

Bioxyne (BXN)

• FY26 revenue visibility from Australia compared with re-acceleration in overseas markets.
• Contract renewals and utilisation of existing capacity.
• Possible capex or licensing moves to broaden product scope without resorting to heavy shareholder dilution.

Marmota (MEU)

• Greenewood assay results due in early October, which could validate or reshape exploration plans.
• Follow-up drilling programs and the potential to define a resource if continuity is confirmed.
• Integration of Greenewood into a larger Gawler district development plan alongside Aurora Tank.

Key Risks to Keep in Mind

Microcaps inherently carry higher risk, and BXN and MEU are no exceptions.

• For Bioxyne: Export market regulations, customer concentration in its B2B model, and working capital management as volumes scale.
• For Marmota: Exploration risk around assay results, funding requirements to sustain drilling, and permitting challenges across a broader district footprint.

The Bottom Line

Some microcaps sprint for quick headlines. Others, like Bioxyne and Marmota, choose the harder but more rewarding road—building scale, proving models, and letting results speak for themselves.

• For Bioxyne, the FY25 pivot to profitability and cash generation signals that its advanced manufacturing “flywheel” has started turning.
• For Marmota, the expanded drilling at Greenewood offers near-term catalysts and the possibility of transforming a single deposit into a district-scale gold story.

For investors willing to take a patient, fundamentals-driven approach, both BXN and MEU stand out as ASX microcaps with the potential to quietly compound long-term value.

Disclaimer:

General Financial Product Advice and Regulatory Framework: Pristine Gaze Pty Ltd (ABN 66 680 815 678, ACN 680 815 678) operates as Corporate Authorised Representative (CAR No. 001312049) of Alpha Securities Pty Ltd (AFSL 330757), which is licensed and regulated by the Australian Securities and Investments Commission under the Corporations Act 2001 (Cth). This report contains general financial product advice only and has been prepared without consideration of your personal objectives, financial situation, specific needs, circumstances, or investment experience. The information is not tailored to individual circumstances and may not be suitable for your particular situation. Before acting on any information contained herein, you should carefully consider its appropriateness having regard to your personal objectives, financial situation, and needs, and consider seeking personal financial advice from a qualified financial adviser who can assess your individual circumstances and provide tailored recommendations.

Investment Risks and Market Warnings: All investments carry significant risk, and different investment strategies may carry varying levels of risk exposure including total loss of invested capital. The value of investments and income derived from them can fluctuate significantly due to market conditions, economic factors, company-specific events, regulatory changes, commodity price volatility, currency fluctuations, interest rate movements, and other factors beyond our control. Securities markets are subject to market risk from general economic conditions and investor sentiment, liquidity risk affecting the ability to buy or sell securities at desired prices, credit risk from issuer default or deterioration, operational risk from inadequate internal processes, sector-specific risks including industry regulatory changes, technology obsolescence, management changes, competitive pressures, supply chain disruptions, and mining-specific risks including resource estimation uncertainty, operational hazards, environmental compliance, permitting delays, commodity price cycles, geopolitical factors affecting mining operations, and exploration risks. Small-cap and speculative mining stocks carry additional risks including limited liquidity, higher volatility, dependence on key personnel, limited operating history, uncertain cash flows, and potential failure to achieve commercial production.

Information Accuracy and Limitations: While we endeavour to ensure information accuracy and reliability, we make no representations or warranties (express or implied) regarding the accuracy, reliability, completeness, timeliness, or suitability of information provided, except where liability cannot be excluded under applicable law. This report may include information from third-party sources including company announcements, regulatory filings, research reports, market data providers, financial news services, and publicly available information, which we do not independently verify and for which we assume no responsibility. Past performance, examples, historical data, or projections are not indicative of future results, and no guarantee of future returns is provided or implied. To the maximum extent permitted by law, Pristine Gaze Pty Ltd and Alpha Securities Pty Ltd, together with their respective directors, officers, employees, representatives, and related entities, exclude all liability for any errors, omissions, inaccuracies, loss or damage (including direct, indirect, consequential, or special damages) arising from reliance on information provided, investment decisions made based on this report, market losses, opportunity costs, and technical issues or system failures.